Anti-Cancer Treatment Strategies in the Older Population: Time to Test More?
Open Access
- 15 April 2021
- journal article
- editorial
- Published by MDPI AG in Geriatrics
- Vol. 6 (2) , 42
Abstract
Aging is a well-recognized risk factor for the development of cancer. The incidence of new cancer diagnoses has increased globally given the rising senior population. Many hypotheses for this increased risk have been postulated over decades, including increased genetic and epigenetic mutations and the concept of immunosenescence. The optimal treatment strategies for this population with cancer are unclear. Older cancer patients are traditionally under-represented in clinical trials developed to set the standard of care, leading to undertreatment or increased toxicity. With this background, it is crucial to investigate new opportunities that belong to the most recent findings of an anti-cancer agent, such as immune-checkpoint inhibitors, to manage these daily clinical issues and eventually combine them with alternative administration strategies of antiblastic drugs such as metronomic chemotherapy.Keywords
This publication has 54 references indexed in Scilit:
- Hallmarks of human “immunosenescence”: adaptation or dysregulation?Immunity & Ageing, 2012
- The PDL1-PD1 Axis Converts Human T H 1 Cells into Regulatory T CellsScience Translational Medicine, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cellsJournal of Experimental Medicine, 2009
- Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrationsJournal of Translational Medicine, 2009
- Myeloid-Derived Suppressor Cells: Linking Inflammation and CancerThe Journal of Immunology, 2009
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- Physiologic Aspects of AgingThe Cancer Journal, 2005
- Role of gammadelta T lymphocytes in tumor defenseFrontiers in Bioscience-Landmark, 2004
- Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment TrialsNew England Journal of Medicine, 1999